ArticleBMC cancer2025
Integrated multi-omics analysis reveals NOL11 as a novel prognostic biomarker for hepatocellular carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most common aggressive malignant tumors worldwide with poor clinical outcomes and high mortality rates, highlighting the pressing need to identify reliable biomarkers. Nucleolar protein 11 (NOL11), as an essential element for ribosomal biosynthesis, has been implicated in the development and progression of various diseases. However, the potential role of NOL11 in HCC remains elusive.
methodsThe expression level of NOL11 was investigated by The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and the correlation between NOL11 and the clinical characteristics was analyzed. Furthermore, spatial-temporal expression patterns of NOL11 were delineated based on single-cell and spatial transcriptomics. Cox regression and ROC analyses were performed to evaluate the prognostic and diagnostic value of NOL11. Additionally, Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and gene set enrichment analysis (GSEA) were conducted to elucidate the functional pathways and potential mechanisms associated with NOL11. The association of NOL11 with immune infiltration was also explored using single-sample Gene Set Enrichment Analysis (ssGSEA). The integrated bioinformatics analysis was utilized to identify the drug sensitivity, and further drug validation was employed via molecular docking. Finally, the biological function of NOL11 was validated through in vitro experiments.
resultsThe expression of NOL11 was significantly upregulated in HCC, especially in tumor cells. Elevated NOL11 levels closely correlated with worse clinicopathological features, poor prognosis, and immune infiltration. Functional enrichment analysis revealed NOL11's potential involvement in multiple cancer-associated signaling pathways, including the cell cycle, DNA replication, and cell metabolism. Furthermore, we found that common chemotherapy drugs, such as gemcitabine, trametinib, and paclitaxel were sensitive to the expression of NOL11 and exhibited a strong molecular combination with NOL11. Lastly, NOL11 knockdown suppressed the proliferation, migration, and invasion of HCC cells.
conclusionOur findings suggest that NOL11 is a promising diagnostic and prognostic biomarker for HCC, providing new insights into the treatment decisions for HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.